Canadian pharmaceutical company Milestone Pharmaceuticals, which is developing an intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia, has announced the appointment of Francis Plat as Chief Medical Officer.
Dr. Plat commented, “I am highly enthused to join Milestone in its development of MSP-2017, a promising product candidate, to alleviate acute episodes of paroxysmal supraventricular tachycardia (PSVT). MSP-2017 is a nasal self-administered treatment-in-the-pocket that will provide a paradigm shift in PSVT treatment by allowing patients to get back to normal life within minutes after the resolution of an episode without the need to go to an emergency room to receive an injectable treatment.”
Milestone CEO Philippe Douville said, “I am excited to welcome Dr. Plat to our team. Dr. Plat’s appointment as Milestone’s Chief Medical Officer comes at a critical juncture for the Company as we prepare for our Phase 2 trials. Dr. Plat is the perfect candidate for our development program given his extensive cardiovascular drug development expertise developed during his career in large pharmaceutical companies.”
The company announced the initiation of a Phase 1 study of MSP-2017 in October 2013.
Read the Milestone Pharmaceuticals press release.
